Key Highlights

  • Amplia Therapeutics (ASX: ATX) entered a clinical collaboration agreement with Eli Lilly to evaluate narmafotinib alongside olomorasib in non-small cell lung cancer.
  • The partnership expands narmafotinib's clinical development beyond pancreatic and ovarian cancer into a larger oncology indication.
  • Share performance is likely to remain closely linked to clinical milestones, partnership progress, and trial execution.
  • The collaboration enhances Amplia's visibility within the global oncology sector through engagement with a major pharmaceutical company.

Amplia Therapeutics (ASX: ATX) continues to attract investor attention as it advances the clinical development of its lead investigational therapy, narmafotinib. The biotechnology company's latest collaboration with Eli Lilly represents an important strategic milestone that broadens its research program into non-small cell lung cancer (NSCLC), one of the world's largest oncology markets. While biotechnology stocks typically experience volatility around clinical developments, Amplia's share performance is increasingly influenced by its expanding pipeline, research partnerships, and progress across multiple cancer indications.

Collaboration with Lilly Expands Clinical Reach

Amplia has signed a Clinical Trial Collaboration and Supply Agreement with Eli Lilly to evaluate narmafotinib in combination with Lilly's investigational KRAS G12C inhibitor, olomorasib.

The planned Phase 1b/2b clinical study will investigate the safety and efficacy of the combination as a second-line treatment for patients with advanced non-small cell lung cancer. The study is expected to commence in late 2026 across clinical sites in Australia and the United States.

The agreement also allows both companies to collaborate on the finalisation of the study protocol, while Lilly will provide in-kind supply of olomorasib for the trial. This structure enables Amplia to pursue development in a significant oncology indication without independently sourcing the investigational therapy.

Broadening the Development Pipeline

Until now, Amplia's clinical development has primarily focused on pancreatic and ovarian cancer. The collaboration introduces non-small cell lung cancer as another therapeutic area for narmafotinib, expanding the company's clinical footprint.

Diversification across multiple cancer indications is an important strategy for biotechnology companies because it reduces reliance on a single development program while increasing opportunities to demonstrate clinical utility across different tumour types.

The expansion also reflects the company's objective of positioning narmafotinib as a combination therapy capable of complementing existing targeted cancer treatments.

Scientific Strategy Supports Combination Approach

The collaboration is supported by growing scientific evidence suggesting that Focal Adhesion Kinase (FAK) plays a role in resistance to KRAS G12C inhibitors.

Current KRAS-targeted therapies have demonstrated clinical activity in certain lung cancer patients; however, treatment resistance remains a significant challenge. Amplia's strategy aims to investigate whether inhibiting FAK alongside KRAS can help overcome resistance mechanisms and improve treatment outcomes.

The study will evaluate narmafotinib in combination with olomorasib, Lilly's next-generation KRAS G12C inhibitor that is currently progressing through late-stage global clinical development.

Although clinical efficacy remains to be established through ongoing research, the biological rationale provides a foundation for continued investigation.

Strategic Partnership Enhances Corporate Profile

Collaborating with a global pharmaceutical company such as Eli Lilly increases Amplia's profile within the biotechnology sector.

Beyond the scientific aspects of the agreement, the collaboration demonstrates industry interest in combination treatment strategies targeting complex cancer pathways. It also enables Amplia to leverage external expertise while expanding clinical research without significantly increasing development complexity.

For investors, strategic partnerships often represent an important indicator of a biotechnology company's ability to attract collaborators capable of supporting long-term development programs.

Conclusion

Amplia Therapeutics (ASX: ATX) has expanded the clinical development pathway for narmafotinib through a collaboration with Eli Lilly targeting non-small cell lung cancer. The agreement broadens the company's oncology pipeline, strengthens its strategic position within combination cancer therapies, and increases its exposure to one of the largest global oncology markets. While biotechnology development remains inherently dependent on clinical outcomes, Amplia's share performance is expected to remain closely aligned with trial execution, partnership progress, and advancements across its expanding clinical portfolio.